Back to results
US 10,792,284 B2Granted
Synergistic cancer treatment
AssigneeMemorial Sloan Kettering Cancer Center
InventorsScott W. Lowe, Neal Rosen, Eusebio Manchado-Robles, Susann Weissmueller
Life of this patent
Estimating the term…
Abstract
The use of mitogen activated kinase inhibition therapy in combination with receptor tyrosine kinase therapy for the treatment of cancer is described.
Claims10
A method for treating a subject that (a) suffers from a KRAS mutant lung or pancreatic cancer, and (b) has received or is receiving a small molecule MEK inhibitor comprising:
- administering to the subject a therapeutically effective amount of a FGFR1 inhibitor, wherein the therapeutically effective amount of the FGFR1 inhibitor is sufficient to significantly reduce lung or pancreatic tumor volume compared to a control subject that is suffering from the KRAS mutant lung or pancreatic cancer and has been treated with the small molecule MEK inhibitor, and wherein the FGFR1 inhibitor is or comprises an antibody agent or a small molecule.
A method of selecting subjects for treatment with a FGFR1 inhibitor comprising:
- (a) detecting elevated FGFR1 levels or activity in tumor samples obtained from subjects suffering from a KRAS mutant lung or pancreatic cancer relative to that observed in a reference sample, wherein the subjects have received a small molecule MEK inhibitor;
- and
- (b) administering to the subjects that express elevated FGFR1 levels or activity a therapeutically effective amount of a FGFR1 inhibitor, wherein the therapeutically effective amount of the FGFR1 inhibitor is sufficient to significantly reduce lung or pancreatic tumor volume compared to a control subject that is suffering from the KRAS mutant lung or pancreatic cancer and has been treated with the small molecule MEK inhibitor, and wherein the FGFR1 inhibitor is or comprises an antibody agent or a small molecule.
A method for treating a subject suffering from a KRAS mutant lung or pancreatic cancer comprising the steps of
- detecting an increase in FRS2 phosphorylation state in a tumor sample obtained from a subject receiving a small molecule MEK inhibitor relative to that observed in a reference sample;
- and
- administering to the subject a therapeutically effective amount of a FGFR1 inhibitor , wherein the therapeutically effective amount of the FGFR1 inhibitor is sufficient to significantly reduce lung or pancreatic tumor volume compared to a control subject that is suffering from the KRAS mutant lung or pancreatic cancer and has been treated with the small molecule MEK inhibitor, and wherein the FGFR1 inhibitor is or comprises an antibody agent or a small molecule.
Dependencies are inferred from the claim text.